Table 3.
Significant Variables in the Final Model of the Stepwise Forward Multivariate Cox-Regression Analyses for Overall Survival (OS) and Progression-free Survival (PFS)
| HR | 95% CI | P-value | |||
|---|---|---|---|---|---|
| Lower bound | Upper bound | ||||
|
OS
(N = 322) |
No glioblastoma treatment | 10.463 | 6.646 | 16.473 | .000 |
| ECOG score ≥ 2 at baseline |
1.791 | 1.322 | 2.426 | .000 | |
| Only biopsy at (diagnostic) surgery | 1.526 | 1.182 | 1.970 | .001 | |
| No MGMT hypermethylation | 1.384 | 1.084 | 1.767 | .009 | |
| At risk of sarcopenia at baseline* | 1.437 | 1.046 | 1.973 | .025 | |
|
PFS
(N = 304) |
No glioblastoma treatment | 8.346 | 5.445 | 12.793 | .000 |
| ECOG score ≥ 2 at baseline |
1.567 | 1.141 | 2.152 | .005 | |
| No MGMT hypermethylation | 1.445 | 1.129 | 1.849 | .003 | |
| At risk of sarcopenia at baseline* | 1.453 | 1.037 | 2.036 | .030 |
* Temporal muscle thickness equal to or below the sex-specific cutoff value
N, number; CI, confidence interval; HR, hazard ratio; ECOG, Eastern Cooperative Oncology Group Performance Status; MGMT, O6-methylguanine-DNA-methyltransferase